VisionGate Featured in Medical Device Daily
Lung cancer test shows high sensitivity, specificity, and early stage detection
At one time a lung cancer diagnosis was considered a death sentence. That’s not necessarily the case today as the field has advanced on both the screening and treatment sides of this disease. Still, the key to winning a battle with any form of cancer is early detection.
Working on the diagnostic side of lung cancer, VisionGate (Phoenix) has developed a test for early stage detection of lung cancer and other applications. Results from a clinical study of the company’s LuCED lung test will be highlighted in a poster presentation later this month during the annual meeting of the American Society of Clinical Oncology (ASCO; Alexandria, Virginia) in Chicago.
